VRPX
NASDAQVirpax Pharmaceuticals Inc.
Latest news
25 items- SECSEC Form 25-NSE filed by Virpax Pharmaceuticals Inc.25-NSE - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)
- SECAmendment: Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits8-K/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- SECVirpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- SECAmendment: SEC Form S-1/A filed by Virpax Pharmaceuticals Inc.S-1/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- SECVirpax Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- PRVirpax Pharmaceuticals Announces Reverse Stock SplitVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company") a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split ("reverse split") of its common stock, par value $0.0001 per share ("Common Stock"), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "VRPX" and will begin trading on a split-adjusted basis when the Nasdaq opens on March 21, 2025 ("Effective
- PRVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced positive results from a beagle dog dose range finding ("DRF") study. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The Company continues to work towards its Investigational New Drug (IND) application and this was another important step towards that milestone. The DRF study was conducted to evaluate the tolerance of Pr
- SECSEC Form S-1 filed by Virpax Pharmaceuticals Inc.S-1 - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- PRVirpax Looking to Use MET to Develop Intranasal COVID VaccineVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look to explore delivery of vaccines via intranasal delivery similar to the FluMist which is used for patients with a fear of needles. The current vaccines in the market use lipid delivery technology to deliver mRNA to induce an immune
- PRVirpax's NES100 to be Presented at The Society of Toxicology by NCATSVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its NES100 dose range finding toxicity study will be presented at The Society of Toxicology (SOT) 64th annual meeting and Tox Expo taking place March 16-20th in Orlando, FL. This is a premier gathering of scientists and professionals in the field of toxicology to advance science in this area. Virpax was previously granted an extension of its cooperative research and development agreement with the National Center
- SECSEC Form 10-K filed by Virpax Pharmaceuticals Inc.10-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- PRVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, would like to congratulate Nanomerics on completing a human study using the Molecular Envelope Technology (MET) and showing no moderate to severe adverse events. Virpax uses MET in its Envelta (NES100) and NobrXiol. Envelta is an enkephalin drug product based on a type of nanotechnology delivery approach. The MET is designed to protect and help carry the drug to the brain with the goal of promptly suppressing pain by binding to the d
- PRVirpax Confirms Positive Results with US Army with Probudur™ for Combat Care StudyVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced the completion of the full study that followed the initial Probudur™ pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA). The USAISR is the U.S. Department of Defense's premier research organization for developing solutions for trauma and critical care challenges in combat casualties. This study was designed to determin
- SECVirpax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- SECVirpax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- PRVirpax's Matthew Barnes to Present at Outsourcing in Clinical Trials ConferenceVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its senior director of portfolio management, Matthew Barnes, will be presenting at Outsourcing in Clinical Trial Conference. The Outsourcing in Clinical Trials (OCT) is a leading conference series for the clinical trial community that takes place worldwide and brings together 1,000+ industry leaders every year to share their success stories and discuss solutions for accelerating clinical trial timelines while m
- SECVirpax Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- PRSpartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On OfferingNEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service investment banking and financial advisory firm, is proud to announce its role as sole placement agent for Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the successful close of its $6 million follow-on offering. Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) is a preclinical-stage pharmaceutical company pioneering novel drug delivery systems for pain management and central nervous system disorders. The proceeds from the offering will enable Virpax to support the ongoing clinical trial development of Probudur, fund marketing and advertising efforts, for general corporate purposes, and to prov
- PRVirpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded WarrantsVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $6.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.20 per share (minus $0.00001 per pre-funded warrant). The Company intends to use the proceeds of the offering to fund its ongoing development activities for commencing clinical trial for its product candidate Probudur, marketing and advertising services to communica
- SECSEC Form 424B4 filed by Virpax Pharmaceuticals Inc.424B4 - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- PRVirpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded WarrantsVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the pricing of its public offering of $0.20 of shares of the Company's common stock, par value 0.00001 per share, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $0.19999 per share (minus $0.00001 per pre-funded warrant). The Company intends to use the proceeds of the offering to fund our ongoing development activities for commencing clinical trial for our product candidate Probudur, marketing and advertising services to communicate
- SECSEC Form EFFECT filed by Virpax Pharmaceuticals Inc.EFFECT - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- SECAmendment: SEC Form S-1/A filed by Virpax Pharmaceuticals Inc.S-1/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- SECAmendment: SEC Form S-1/A filed by Virpax Pharmaceuticals Inc.S-1/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
- SECVirpax Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
VRPX FAQ
6 questionsWhat does Virpax Pharmaceuticals Inc. do?
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of...Where does VRPX stock trade?
Virpax Pharmaceuticals Inc. (VRPX) is listed on NASDAQ.What sector and industry is VRPX in?
Virpax Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Virpax Pharmaceuticals Inc. go public?
Virpax Pharmaceuticals Inc. (VRPX) completed its IPO in 2021.What companies are similar to VRPX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare VRPX side-by-side with any of them on Quantisnow.How can I track VRPX on Quantisnow?
Quantisnow aggregates Virpax Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VRPX to receive live email and push alerts on every new disclosure.